首页> 外文OA文献 >Formulation and stability testing of eye drop preparations containing phenylephrine hydrochloride
【2h】

Formulation and stability testing of eye drop preparations containing phenylephrine hydrochloride

机译:含有盐酸去氧肾上腺素的滴眼剂制剂的配方和稳定性试验

摘要

Phenylephrine hydrochloride is a potent adrenergic agent and β-receptor sympathomimetic drug, used in its optically active form (Pandey et al., 2003; Pandey et al., 2006). As an α1-adrenergic receptor agonist, phenylephrine hydrochloride is used ocularly as a decongestant for uveitis and as an agent to dilate the pupil (Lang, 1995). High intraocular doses have been reported to cause tachycardia, hypertension, and headache. These side effects are caused by large amounts of the drop draining into the nasal cavity. Eye drops that contain phenylephrine hydrochloride have proven to have low intra-ocular bioavailability because of a short contact time with the eyes which reduces the amount of drug reaching the site of action. Formulations of phenylephrine hydrochloride eye drops have varying shelf-lives of approximately two to four years. The aim of this study was to formulate and manufacture an eye drop product containing phenylephrine hydrochloride. Important characteristics that were targeted were increased ocular absorption by increasing the viscosity of the product and reduced degradation of phenylephrine hydrochloride. A variety of phenylephrine hydrochloride formulations were manufactured on a laboratory scale using hydroxypropyl methylcellulose (HPMC), glycerol, and sodium carboxy methylcellulose as viscosity modifying agents (VMA). The concentration of phenylephrine hydrochloride was ten percent. Ten millimeters of each formulation was made in triplicate. The quantity in each was evaluated using a previously validated high performance (pressure) liquid chromatography method. Physicochemical properties including pH and colour were also evaluated. Stability was assessed using real time and accelerated stability conditions in accordance with the International Conference on Harmonization (ICH) guidelines. Formulations containing hydroxypropyl methylcellulose (HPMC) as the viscosity modifying agents proved to be stable under all storage conditions when compared with formulations containing other viscosity modifying agents (VMA). However, sodium citrate dihydrate; sodium metabisulphite and EDTA also stabilized the formulations to a certain extent Changes in the appearance and colour of products containing glycerol under accelerated storage conditions were observed. The sodium carboxy methylcellulose (SCMC) containing formulation was found to be physically and chemically stable in two conditions, namely 30 °C/65 percent RH and 25 °C/60 percent RH. The formulations containing hydroxypropyl methylcellulose along with an antioxidant showed to be most stable as it remained aesthetically pleasing did not change colour and did not have a reduction in phenylephrine hydrochloride concentrations. This meant that phenylephrine hydrochloride did not degrade while the viscosity modifying agents remained stable. Rheological tests showed differences in the viscosities of the formulations as glycerol had increased in viscosity over time while HMPC and SCMC displayed relative similarities. The formulations were compared to a marketed eye drop containing polyvinyl alcohol as a VMA. After rheological analysis the formulation containing HPMC displayed better viscosity than the product with polyvinyl alcohol. The preservatives in the formulations were active against the microbial organisms use to challenged them.
机译:盐酸去氧肾上腺素是一种有效的肾上腺素能药物和β受体拟交感神经药,以其光学活性形式使用(Pandey等,2003; Pandey等,2006)。作为α1-肾上腺素能受体激动剂,盐酸去氧肾上腺素在眼中用作葡萄膜炎的充血剂和扩张瞳孔的药物(Lang,1995)。据报道,高眼内剂量可引起心动过速,高血压和头痛。这些副作用是由于大量液滴滴入鼻腔引起的。含有苯肾上腺素盐酸盐的滴眼液由于与眼睛的接触时间短而被证明具有较低的眼内生物利用度,从而减少了到达作用部位的药物量。盐酸去氧肾上腺素滴眼液的配方具有大约两到四年的不同保存期限。这项研究的目的是配制和制造含有盐酸去氧肾上腺素的滴眼剂产品。所针对的重要特征是通过增加产品的粘度来增加眼吸收,并减少盐酸去氧肾上腺素的降解。使用羟丙基甲基纤维素(HPMC),甘油和羧甲基纤维素钠作为粘度调节剂(VMA),以实验室规模生产了多种去氧肾上腺素盐酸盐制剂。盐酸去氧肾上腺素的浓度为百分之十。一式三份制备每种配方十毫米。使用先前验证的高性能(压力)液相色谱法评估每种物质的含量。还评估了包括pH和颜色在内的理化性质。根据国际协调会议(ICH)指南,使用实时和加速稳定性条件评估稳定性。与包含其他粘度调节剂(VMA)的制剂相比,包含羟丙基甲基纤维素(HPMC)作为粘度调节剂的制剂在所有储存条件下均证明是稳定的。但是,柠檬酸钠为二水合物。偏亚硫酸氢钠和EDTA也使制剂稳定到一定程度,在加速储存条件下观察到了含有甘油的产品的外观和颜色变化。发现含有羧甲基纤维素钠(SCMC)的制剂在两种条件下,即30°C / 65%RH和25°C / 60%RH在物理和化学上是稳定的。含有羟丙基甲基纤维素和抗氧化剂的配方表现出最稳定的效果,因为它保持美观,不会改变颜色,也不会降低苯肾上腺素盐酸盐的浓度。这意味着盐酸去氧肾上腺素不会降解,而粘度调节剂保持稳定。流变测试表明,随着甘油的粘度随时间增加,配方的粘度有所不同,而HMPC和SCMC则显示出相对的相似性。将制剂与含有聚乙烯醇作为VMA的市售滴眼剂进行比较。流变分析后,包含HPMC的配方的粘度比含聚乙烯醇的产品更好。制剂中的防腐剂具有抵抗微生物攻击微生物的作用。

著录项

  • 作者

    Okafor Chinedum Oluchukwu;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种 English
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号